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Abstract
Background: Unresectable biliary tract carcinoma is known to demonstrate a poor prognosis. We conducted
a single arm phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose
consecutive (Cisplatin) CDDP) for advanced biliary tract malignancies basically on an outpatient basis.
Methods: Between February 1996 and September 2003, 42 patients were enrolled in this trial.
LFP therapy: By using a total implanted CV-catheter system, 5-FU (160 mg/m2/day) was continuously infused
over 24 hours for 7 consecutive days and CDDP (6 mg/m2/day) was infused for 30 minutes twice a week as one
cycle. The administration schedule consisted of 4 cycles as one course. RESIST criteria (Response evaluation
criteria for solid tumors) and NCI-CTC (National Cancer Institute-Common Toxicity Criteria) (ver.3.0) were
used for evaluation of this therapy. The median survival time (MST) and median time to treatment failure (TTF)
were calculated by the Kaplan-Meier method.
Results: Patients characteristics were: mean age 66.5(47–79): male 24 (54%): BDca (bile duct carcinoma) 27
GBca (Gallbladder carcinoma) 15: locally advanced 26, postoperative recurrence 16. The most common toxicity
was anemia (26.2%). Neither any treatment related death nor grade 4 toxicity occurred. The median number of
courses of LFP Therapy which patients could receive was two (1–14). All the patients are evaluable for effects
with an over all response rates of 42.9% (95% confidence interval C.I.: 27.7–59.0) (0 CR, 18 PR, 13 NC, 11 PD).
There was no significant difference regarding the anti tumor effects against both malignant neoplasms. Figure 2
Shows the BDca a longer MST and TTF than did GBca (234 vs 150, 117 vs 85, respectively), but neither difference
was statistically significant.
The estimated MST and median TTF were 225 and 107 days, respectively. The BDca had a longer MST and TTF
than GBca (234 vs 150, 117 vs 85, respectively), but neither difference was statistically significant.
Conclusion: LFP therapy appears to be useful modality for the clinical management of advanced biliary tract
malignancy.
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Background
Biliary tract cancers are rare in North America, with
approximately 8,000 new cases diagnosed in 2003 [1].
However, bile duct carcinoma (BDca) and gallbladder car-
cinoma (GBca) are not rare in northern Japan [2], Taiwan
[3], and South Korea [4]. In Japan, these malignancies are
the sixth leading cause of cancer deaths, and in 1999,
there were 8,557 deaths from BDca and 6,340 deaths from
GBca [5]. As an surgical resection of the primary tumor
and the areas of local extension remains the most effective
therapy [6], even for non-curative operations [7]. How-
ever, in over 75% of the patients whose disease is locally
advanced or already metastatic cases, the median survival
time for patients receiving only the best possible support-
ive care is only about 6 months [1]. Furthermore, there is
a high rate of both local and systemic recurrence, even
after a curative resection [1,6]. As a result, an effective
chemotherapy for biliary malignancy has been eagerly
awaited. However, systemic single-agent chemotherapy
has so far shown a poor efficacy [6,8], though many
efforts has been done [9]. For example, the response rate
of 5-fluorourasil (5-FU), cisplatin (CDDP), was 10–13%,
and 8%, respectively [4], while new chemotherapeutic
agents CPT-11, Gemsitabine, showed the poor response
rate of 12.5% and 8%, respectively [3,4,10].
As a result, an effective combination chemotherapy has
been eagerly anticipated. We spotlighted the combination
of the two old anti-cancer agents, 5-FU, and CDDP.
In Japan, FP therapy combination of 5-FU continuous
venous infusion (CVI) and low-dose consecutive CDDP
(LFP) Therapy has been widely used since early 1990s for
gastrointestinal advanced cancer [11,12]. Because of its
low toxicity and relatively high response rate [13], LFP
therapy has been widely used for the treatment of various
unresectable advanced solid tumors, such as gastric cancer
[14], hepatocellular carcinoma [15], pancreatic cancer
[12], colon and head and neck [11]. Recent findings in
experimental models have shown an additive or synergis-
tic antitumor effects of LFP therapy. We observed that
CDDP inhibited metionine transport into tumor cells,
both in vitro and in vivo, with a synergic interaction by
CDDP functioning as a modulator of 5-FU [11,12]. This
synergistic effect was also associated with the induction of
apoptosis [16] and the p53 pathway [17,18].
Based on these findings, we conducted a single arm phase
II study of LFP therapy in patients with advanced BDca
and GBca.
Methods
Eligibility criteria
This study protocol was approved by the Kochi Municipal
Central Hospital, Japan and written informed consent was
obtained from all the patients. The patients were required
to have unresectable locally advanced or metastatic dis-
ease of the biliary-tract or gallbladder advanced carci-
noma with measurable lesions on a computed
tomography (CT) scan. Other eligibility criteria included
an age 18 years or more, Eastern Cooperative Oncology
Group (ECOG) performance status of 2 or less, estimated
life expectancy of 12 weeks or more, adequate bone mar-
row function (leukocyte count > 3,500/µl, neutrophil
count > 1,500/µl, and platelet count > 100,000/µl),
bilirubin < 5.0 mg/dl, transaminases and alkaline phos-
phatase < 6 times upper limit of normal, and normal renal
function tests (creatine level < 1.5 mg/dl, or creatinine
clearance > 60 ml/min). No previous chemotherapy was
permitted within 2 weeks. Radiotherapy and stenting to
decompress the biliary tract was permitted. Patients with
other clinically significant laboratory abnormalities,
uncontrolled infection, concurrent severe medical prob-
lems unrelated to malignancy that would expose the
patient to extreme risk, patients receiving another investi-
gational drug within 30 days prior to study or receiving
concurrent hormonal therapy, immunotherapy and those
pregnant or lactating were excluded from the study. The
study was conducted according to the Good Clinical Prac-
tices and the Declaration of Helsinki as amended in Hong
Kong (1989).
Treatment plans
All patients were admitted to the hospital for about 10
days for a pretreatment evaluation, the first cycle treat-
ment, and observation for adverse effects. If the degree of
toxicity was within Grade 0–2, a second cycle of treatment
or more were continued on an outpatient basis.
A pretreatment evaluation included complete medical his-
tory, physical examination, evaluation of performance
status, urinalysis, chest radiograph, and diagnostic studies
assessment such as CT scan. When the patient meets the
eligibility criteria, central venous catheter system with a
heparin coated catheter (Anthron PU catheter; TORAY™
and a port (Celcite brachial; TORAY™ or Vital port mini;
COOK™) is implanted according to the method of Hata et
al [19] prior to treatment.
The treatment plan involved the administration of 5-FU
(160 mg/m2/day) was continuously infused over 24 hours
using a disposable infusion pump (7-day Infuser; Bax-
ter™) and CDDP (3–6 mg/m2/day) diluted with normal
serine was infused for half an hour. Hydration was not
needed. These doses were determined based on our expe-
rience of the previous LFP therapy for hepatocellular car-
cinoma [15]. The administration schedule consisted of 5-
FU for 7 consecutive days and CDDP twice a week (day 1
and day 4) for each of four weeks as one treatment course.
The treatment schedule and CV catheter system wasBMC Cancer 2006, 6:121 http://www.biomedcentral.com/1471-2407/6/121
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depicted on figure 1. Unless an exacerbation of the symp-
toms was observed, multiple courses of treatment were
administered. When more than a grade 3 adverse effect
was observed, a CDDP infusion was omitted and
observed. If this omission was ineffective, 5-FU was also
omitted. In case of hemoglobin < 8.0 g/dl, platelet count
< 50,000/µl neutrophil count < 1,000/µl, blood transfu-
sion of concentrated red blood cells (RBCs) or platelets, or
granulocyte-stimulating factor (G-CSF) was applied.
We do not increase the dose of the anti-cancer agent dur-
ing the chemotherapy protocol, even if the toxicity is low.
Toxicity and response evaluation
Complete blood counts twice a week and biochemical
examinations were weekly carried out. Toxicity was evalu-
ated based on the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) ver.3. The response was clas-
sified based on the Response Evaluation Criteria in Solid
Tumors Guidelines (RECIST criteria) [20], taking into
account the measurement of the longest diameter only for
all target lesions: complete response (CR)-the disappear-
ance of all target lesions; partial response (PR)-at least a
30% decrease in the sum of the longest diameter of target
lesions, taking as reference the baseline sum longest diam-
eter; progressive disease (PD) -at least a 20% increase in
the sum of the longest diameter of target lesions, taking as
referenve the smallest sum longest diameter recorded
since the treatment started or the appearance of one or
more new lesions; no change (NC)-neither sufficient
shrinkage to quality for partial response nor sufficient
increase to qualify for progressive disease, taking as refer-
ence the smallest sum longest diameter since the treat-
ment started. Patients with a CR, a PR, an NC, or a PD
required a confirmatory disease assessment at least one
Schedule for treatment and infusional method Figure 1
Schedule for treatment and infusional method. A schematic drawing of the chemotherapy schedule (a), and the Central 
Venous catheter system consists of PAS port (b), implantation technique (c) and portable infusion pump (d).
Schedule for treatment and infusional method
Continuous infusion 5-FU 160mg/m2/day
1234567123456712345671234567 CDDP   3-6mg/m2/day day
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month later. Target lesions were evaluated by a plain and
enhanced CT scan and plain chest X-ray for each course.
Statistical analyses
We used the Stat View J 5.0 software package (Abacus
Concepts, Stat View. Abacus Concepts, Inc., Berkeley, CA,
1992–1998) for the statistical analysis. The time to Treat-
ment Failure and the overall Survival Cumulative were
obtained by the Kaplan-Meier method. The disease-free
survival was compared by the Log rank test among the
groups. Prognostic variables were evaluated by Cox's mul-
tivariate proportional hazard model. We defined the risk
factors for LFP therapy for biliary tract malignancies in our
study as significant factors based on both the Cox's and
Kaplan-Meier's. A p value of less than 0.05 was considered
to be statistically significant.
Results
Patient characteristics
From February 1996 to December 2003, 42 patients were
enrolled into the present study, and all were evaluable for
efficacy and toxicity analyses. They consisted of 24 males
and 18 females. The mean age was 66.5(47–79). The
number of patients with BDca and GBca were 27 and 15,
respectively. Twenty-six patients who were initially diag-
nosed to have biliary tract malignancies were not eligible
for surgery because of locally advanced disease and/or
metastasis (locally advanced). Another 16 patients had
local recurrence and/or distant metastasis after surgery
(postoperative recurrence). Disease extension was such
that 11 patients (BDca: 7, GBca: 4), had only primary or
local recurrence patients had only metastatic disease
(BDca: 9, GBca: 5), another 17 patients (BDca:11, GBca: 6)
had both diseases. Four patients had previously undergone
Survival and Treatment failure Figure 2
Survival and Treatment failure. Kaplan-Meier curves of Overall Survival (upper column) and Time to treatment failure (TTF) 
(lower column) are shown.
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Figure 2.
Overall Survival Curve
TTF curve
BDca    234 days
GBca    150 days
MST
p=0.4763
Over all   225 days
   
   
   
BDca    117 days
GBca    85 days
mTTF
p=0.3014
Over all   107 days    
   
   
(BDca: Bile duct carcinoma GBca: Gallbladder carcinoma)
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chemotherapy, including such treatments as CDDP + VP-
16, 5-FU + mitomycin C + farmorubicin, adriamycin + 5-
FU. Two of 4 patients experienced surgery before these
chemotherapy (i.e. postoperative recurrence). Seven of
BDca patients had palliative radiotherapy. Three of these
seven underwent surgery before radiation (i.e. postopera-
tive recurrence). There were some differences between
BDca and GBca on age, and serum tumor marker levels
(CEA and CA19-9), but neither was statistically significant.
The patient characteristics are enumerated in Table 1.
Response and time-to-event measures
The overall response rate (RR) was 42.9% (95% confi-
dence interval C.I.: 27.7–59.0) with CR 0, PR 18, NC 13,
PD 11, and clinical benefit was 73.8% (95% C.I.: 58.0–
86.2). Patients with a PR, an NC or a PD required a con-
firmatory disease assessment at least two months later.
One GBca patient who got PR, could receive curative
resection. The RR of primary lesion or locally advanced
lesion was 50.0% (95% C.I.: 30.6–69.4), and the RR of
Table 1: Patient Characteristics
Variables Startification Over all BDca GBca
Spieces of cancer 42 27 15
Sex (male/female) (24/18) (17/10) (7/8)
Age 66.5 ± 7.5 64.8 ± 8.2 69.5 ± 4.7
ECOG PS (0/1/2) (36/4/2) (22/4/1) (14/0/1)
Disease Status (unresectable/postoperative recurrence) (26/16) (15/12) (11/4)
Disease extension locally advanced (primary) 26 15 11
local recurrence 7 7 0
liver metastasis 9 4 5
lung metastasis 4 3 1
lymphnode metastasis 11 4 7
miscellaneous metastasis 5 5 0
Tumor marker carcinoembryonic antigen (CEA) 16.7 ± 60.7 6.4 ± 17.2 36.7 ± 100.5
CA19-9 3035.5 ± 9507.6 4495.3 ± 11688.8 407.9 ± 587.2
Previous chemotherapy (yes/no) (4/38) (3/24) (1/14)
Abbreveations
BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status
Table 2: Anti tumor effect
Over all
CR PR NC PD Response Rate (%)95%C.I. CR+PR/TOTAL Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all 0 18 13 11 42.9 (27.7–59.0) 73.8 (58.0–86.2)
BDca 0 11 10 6 40.7 (22.4–61.2) 77.8 (57.8–91.4)
GBca 0 7 3 5 46.7 (21.1–73.5) 66.7 (38.4–88.2)
Primary or local recurrence
CR PR NC PD Response Rate (%)95%C.I. CR+PR/TOTAL Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all 0 14 8 6 50.0 (30.6–69.4) 78.6 (59.0–91.7)
BDca 0 9 6 3 50.0 (26.0–74.0) 83.3 (58.6–96.5)
GBca 0 5 2 3 50.0 (18.6–81.4) 70.0 (34.7–93.5)
Metastatic lesion
CR PR NC PD Response Rate (%)95%C.I. CR+PR/TOTAL Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all 0 10 12 9 32.3 (16.7–51.4) 71.0 (52.0–85.8)
BDca 0 6 9 5 30.0 (11.8–54.3) 75.0 (50.9–91.4)
GBca 0 4 3 4 36.4 (10.8–69.3) 66.7 (30.7–89.2)
Abbreveations
BDca: bile duct carcinoma, GBca: Gallbladder carcinomaBMC Cancer 2006, 6:121 http://www.biomedcentral.com/1471-2407/6/121
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metastatic lesions was 32.3%. Various RRs were demon-
strated in Table 2. The responses of meatastatic lesions
were as such; liver (CR:0, PR:6, NC:0, PD:3), lung (CR:0,
PR:1 NC:3, PD:0), lymph node (CR:0, PR:3, NC: 6, PD2),
miscellaneous (CR:0, PR: 2, NC: 2, PD: 1). There was no
significant difference in terms of anti tumor effects against
both malignant neoplasms. The overall MST was 225
days. The median TTF was 107 days. Figure 2 Shows the
BDca a longer MST and TTF than did GBca (234 vs 150,
117 vs 85, respectively), but neither difference was statis-
tically significant.
Toxicity
As shown in Table 3, neither any treatment related death
nor grade 4 toxicity occurred. Overall, the most common
toxicity was anemia occurring in 26.2% of patients fol-
lowed by nausea (19.0%). The most frequent grade 3 tox-
icity was appetite loss (14.3%). The occurrence of ascites
and jaundice may be partly because of the outcome of the
disease progression.
Prognostic factors related survival and TTF
An analysis of a Cox proportional hazard model showed
that no significant factor was found prognostic factors for
either the overall survival or TTF (Table 4). However, the
patients with LFP courses 2 had both a longer overall
survival and TTF than those with LFP courses < 2 as
depicted in Figure 3. The distribution of the patients with
LFP courses 2 was (PR/NC/PD = 16/8/3), while that of
those with LFP courses ≤2 was (PR/NC/PD = 2/5/8).
Table 3: Toxicity
Hematological Toxicity Gr1 Gr2 Gr3 Gr4 Gr3 (%) Over all (%)
anemia 0 11 0 0 0 (0) 11 (26.2)
leukopenia 0 1 0 0 1 (0) 1 (2.3)
thrombocytopenia 0 2 3 0 3 (7.1) 5 (11.9)
Non-hematological Toxicity Gr1 Gr2 Gr3 Gr4 Gr3 (%) Over all (%)
n a u s e a 3410 1  ( 2 . 3 ) 8  ( 1 9 . 0 )
v o m i t i n g 1130 1  ( 2 . 3 ) 5  ( 1 1 . 9 )
appetite loss 0 0 6 0 6 (14.3) 6 (14.3)
oral mucositis 0 4 0 0 0 (0) 4 (9.5)
taste disturbance 0 1 0 0 1 (2.3) 1 (2.3)
upper GI tract bleeding 0 1 0 0 0 (0) 1 (2.3)
diarrhea 1 0 0 0 0 (0) 1 (2.3)
general fatigue 0 1 1 0 1 (2.3) 2 (4.7)
jaundice 0 0 4 0 4 (9.5) 4 (9.5)
serum AST/ALT level elevation 0 4 1 0 1 (2.3) 1 (2.3)
Serum creatinine level elevation 0 6 0 0 0 (0) 6 (14.3)
Table 4: Prognostic factors for over all survival and TTF
Over all survival Time to treatment Failure
Stratification Hazard ratio p-value 95% C.I. Hazard ratio p-value 95% C.I.
Sex (male/female) 0.123 0.0128 0.024–0.640 0.225 0.0095 0.073–0.695
Age (69/<69) 0.634 0.6082 0.111–3.692 2.380 0.2269 0.583–9.713
ECOG PS (PS0/PS1/PS2) 0.016 0.0015 0.001–0.259 0.230 0.0007 0.001–0.152
Species of tumor (BDca/GBca) 0.095 0.0198 0.013–0.688 0.001 0.0411 0.0856–0.943
Disease status (locally advanced/postoperative recurrence) 0.121 0.0179 0.021–0.695 0.802 0.7388 0.001–0.152
Radiation (yes/no) 8.369 0.1491 0.467–150.112 0.603 0.4586 0.158–2.299
Previous chemotherapy (yes/no) 0.143 0.0255 0.016–1.241 0.495 0.4086 0.094–2.622
Initial CEA level (1 UL/<1 UL) 1.098 0.9053 0.234–5.160 2.453 0.1267 0.775–7.763
Interval decreasing CEA level (yes/no) 0.224 0.2859 0.014–3.499 1.734 0.5968 0.260–11.568
Initial CA19-9 level (5 UL/<5 UL) 0.078 0.0255 0.014–3.499 1.734 0.5968 0.260–11.568
Interval decreasing CA19-9 level(yes/no) 1.449 0.7667 0.125–16.774 0.326 0.2600 0.047–2.290
(Cox proportional hazard model)
Abbreveations
BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status, CEA: 
carcinoembryonic antigen, UL: upper limitBMC Cancer 2006, 6:121 http://www.biomedcentral.com/1471-2407/6/121
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Cost benefit
The difference between the inpatient-basis and the outpa-
tient-basis or home treatment of this therapy in respect to
cost is shown in Table 5. This was calculated based on the
assumption that one patient received one-month treat-
ment of this LFP therapy covered by Japanese National
Health Insurance. The cost for outpatient-basis/home LFP
therapy was approximately equivalent to 996 U.S. dollars
which was about one-sixth less than the cost on an inpa-
tient-basis.
Discussion
In the present study, we achieved an RR of 42.9% (95%
C.I.: 27.7–59.0) with a median over all survival of 225
days and median TTF of 107 days. No grade 4 toxicity or
treatment related death occurred. The cause of treatment
failure of the other 37 patients was an aggravation of gen-
eral condition due to primary disease, and not due to any
adverse effect. LFP therapy showed a good compliance
and the adverse effects were either tolerable or controlla-
ble.
The overall response rate of our study is relatively high for
this type of tumor. However, our LFP method has
achieved more than a 50% overall response rate in other
tumors such as esophageal, gastric or colon cancers. Bil-
iary tract cancer may be more malignant than other types
of cancer.
One cycle of conventional LFP therapy consists of CDDP
infusion consecutive five days per week and 24 hr contin-
uous infusion of 5-FU consecutively 7 days per week [14].
Relation between number of LFP courses and Over all survival and TTF Figure 3
Relation between number of LFP courses and Over all survival and TTF. Differences by accomplished LFP (5-FU (5-fluor-
ourasil) continuous infusion and Low-Dose Consecutive Cisplatin(CDDP)) courses are depicted regarding the overall Survival 
(upper column) and Time to treatment failure (TTF)(lower column).


    





Over all survival (days)
a
c
c
u
m
a
l
a
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
 
(
%
)


    





Time to Treatment Failure (days)
a
c
c
u
m
a
l
a
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
 
(
%
)
Overall Survival Curve
TTF curve
MST
LFP     2 courses   279 days
LFP     2 courses   98 days
   
   
mTTF
LFP     2 courses   140 days
LFP     2 courses   41 days P   0.0001
   
   
Figure 3. Relation between number of LFP courses and Over all 
survival and TTF
LFP:5-FU (5-fluorourasil) continuous infusion
and Low-Dose Consecutive Cisplatin(CDDP)
P   0.0001BMC Cancer 2006, 6:121 http://www.biomedcentral.com/1471-2407/6/121
Page 8 of 10
(page number not for citation purposes)
Therefore, the patients were obliged to receive inpatient-
basis treatment, which led to their inconvenience and a
heavy burden due to the high admission fee. Regarding
the five consecutive days of CDDP infusion, our prelimi-
nary study showed that CDDP infusion twice a week was
sufficient to maintain the blood concentration of CDDP
in order to achieve synergistic effect [15]. This fact and the
application of a CV catheter system with PAS or vital port
and portable infusion pump thus enable the patients to
receive outpatient-basis treatment which is equivalent to
the inpatient treatment in quality. As for central venous
catheter, Knox reported six catheter infection cases
occurred in 27 patients [6], but no complications related
to the catheter system occurred in our study. Our good
results were due to the easy technique of implantation
associated with the catheter system [19]. In our hospital
from July 1994 to December 2002, infection related to the
CV-catheter system occurred in only 44 cases of total
1,350 implanted patients (3.4%).
We herein tried to compare our regimen with other com-
bination chemotherapies [2,4-6,21-23] are summarized
in Table 6. Our combination chemotherapy is thus con-
sidered to be effective enough to be recommended the bil-
iary tract malignancy since our study achieved a low
toxicity and high efficacy with a relatively higher RR and
longer MST in comparison to these regimens. Kim's regi-
men [4] is also interesting since oral capesitabine was
used. However, our results showed higher response rate
and lower toxicity than Kim's.
Table 6: Current Combination Chemotherapy for Biliary tract cancer
Author 
(published year)
Number of 
Patients
Species 
of cancer
Regimen RR (%) MST 
(days)
mTTF 
(days)
Adverse effects (Gr3) Treatment 
related death
Ishii(2004) 21 GBca CEF(CDDP/5-FU/
epirubicin)
33.3 177* - hematological toxicity 
(52.3%)
none
25 GBca FAM(5-FU/Doxorubicin/
Mitomycin)
7.1 - hematological toxicity (20%) none
Lee (2004) 4 BDca Gemsitabine/CDDP 50 270 150 thrombocytopenia (75%) none
Doval(2004) 30 GBca Gemsitabine/CDDP 36.6 140 126 nausea/vomiting (16%) 2
Malik(2003) 11 GBca Gemsitabine/CDDP 64 294 196 anemia (45%) none
Knox (2004) 27 BDca/
CBca
Gemsitabine/5-FU 33 159 111 hematological toxicity (11%) none
Malik(2003) 30 CBca Leucovorin/5-FU 7.5 444 141 diarrhea (30%) 1
Kim (2003) 42 BDca/
CBca
Capesitabine/CDDP 21.4 273 111 leucopenia (20%) none
(* The result was overall survival of combined CEF and FAM)
Abbreveations
BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, CDDP: Cisplatin, 5-FU: 5-fluorourasil, RR: response rate, MST: median survival time, 
mTTF: median time to treatment failure
Table 5: Cost-benefit
Outpatient-basis or home Inpatient-basis
At home malignant tumor Basic admission fee 472,900 yen
Administration fee 25,000 yen Local infusion technical fee (addition to minute infusion) 46,200 yen
Portable infuser pump
using fee 15,000 yen Diet 63,600 yen
Medication Medication
CDDP 20,000 yen CDDP 20,000 yen
5-FU 15,000 yen 5-FU 15,000 yen
Tumor marker 5,000 yen Tumor marker 5,000 yen
Other laboratory test 8,400 yen Other laboratory test 8,400 yen
Imaging diagnosis 15,000 yen Imaging diagnosis 15,000 yen
(antiemeric drug 16,000 yen) (antiemeric drug 16,000 yen)
Total 103,600 (119,600) yen Total 646,300 (662,300) yen
(One month treatment covered by Japanese National Health Insurance, A U.S. dollar is approximately equivalent to 104 Japanese yen)BMC Cancer 2006, 6:121 http://www.biomedcentral.com/1471-2407/6/121
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One of the problems of our study was that the prognosis
of the patients receiving less than two courses of LFP was
remarkably poor as shown in Figure 3. Of these patients
only one could receive second-line chemotherapy with
CDDP/CPT-11. It is important to predict whether LFP
therapy is effective or not. Fortunately, an effective
method for predicting LFP therapy effectiveness for gas-
trointestinal cancers by detecting p53 has been reported
[16-18]. This method may be applicable for biliary tract
malignancy.
The present study used 5-FU continuous venous infusion
(CVI) as an effector. If an oral drug which can help main-
tain a high blood concentration of 5-FU equivalent to or
higher than that for the CVI-method exist, then the
patients with biliary tract malignancy can avoid the need
to use the catheter system but while still achieving an
improved anti-tumor effect thus leading to an advanced
quality of life. S-1 invented by one of the authors (T.S)
[11] can thus be one of the candidates for this aim. S-1 is
a novel oral fluoropyrimidine that consists of tegafur,
which is a prodrug of 5-FU, 5-chloro-2, 4-dihydroxypyri-
midine, which inhibits dihydropyrimidine dehydroge-
nase activity and potassium oxonate, which reduces
gastrointestinal toxicity [11,24]. This feature helps to
maintain a high blood concentration of 5-FU and less tox-
icity of digestive tract [11,24]. The result of 101 advanced
gastric cancer patients with S-1 was reported to be 44.6%
RR with 244 days of MST [25,26]. Furthermore, using the
synergistic effect of LFP, the combination chemotherapy
of CDDP and S-1 has also been performed for gastric can-
cer or pancreatic cancer at some institutes [13,25,27-30].
Many reports have so far described promising results. The
application of low-dose CDDP and S-1 for biliary malig-
nancies at our institute is now under consideration. Our
study of LFP is thus considered to support the use of low-
dose CDDP and S-1 regimen for BDca and GBca.
Conclusion
In conclusion, this outpatient-basis LFP therapy is consid-
ered to be appropriate as a first-line treatment for either
advanced or recurrent biliary tract cancer and it promises
to help improve the quality of life of cancer patients while
also facilitating the clinical management of such patients.
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